Skip to main content
SpringerLink
Log in

Vaccine Therapy in Sarcoma

  • Chapter
  • First Online:
Immunotherapy of Sarcoma

  • 479 Accesses

Abstract

Vaccine therapy has been a widely explored immunotherapy modality in sarcoma. Ongoing studies continue to explore its future role in the therapeutic landscape of sarcoma. Many subtypes of sarcoma are ideal vaccine targets given their wide expression of immunogenic proteins and antigens, including cancer-testis antigen family (NY-ESO-1, MAGE-A3, PRAME, and LAGE-1), gangliosides (GM2, GD2, and GD3), and sarcoma-specific fusion proteins (SSX, FOXO1, EWSR1, and TLS CHOP). These sarcoma features and others, including tumor lysate and dendritic cells pulsed with antigen, have been exploited in various vaccine strategies. While vaccine therapy has induced some responses in sarcomas, further research will help to identify optimal treatment strategies in these patients and tailoring of immunotherapeutic approaches by sarcoma subtype and each unique biology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ward S, et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother. 2002;51:351–7.

    Article  Google Scholar 

  2. Coley WB. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14:199–220.

    Article  CAS  Google Scholar 

  3. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630–41.

    Article  CAS  Google Scholar 

  4. Scanlan MJ, et al. The cancer/ testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.

    PubMed  Google Scholar 

  5. Lai J-P, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012;25(6):854–8.

    Article  Google Scholar 

  6. Dhodapkar MV, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6(232):232ra51.

    Article  Google Scholar 

  7. Pollack S, et al. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. J Clin Oncol. 2017;35(15 suppl):3090.

    Article  Google Scholar 

  8. Mitsis D, et al. Current immunotherapies for sarcoma: clinical trials and rationale. Sarcoma. 2016;2016:9757219.

    Article  Google Scholar 

  9. Ayyoub M, et al. SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun. 2003;3:13.

    PubMed  Google Scholar 

  10. Kawaguchi S, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med. 2005;3(1):1.

    Article  Google Scholar 

  11. Matsuzaki A, et al. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol. 2002;24(3):220–3.

    Article  Google Scholar 

  12. Guo C, et al. Therapeutic cancer vaccines: past, present and future. Adv Cancer Res. 2013;119:421–75.

    Article  CAS  Google Scholar 

  13. Ghisoli M, et al. Three-year follow up of GM-CSF/bi-shRNAfurin DNA-transfected autologous tumor immunotherapy (Vigil®) in metastatic advanced Ewing’s sarcoma. Mol Ther. 2016;24(8):1478–83.

    Article  CAS  Google Scholar 

  14. Chang HR, et al. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer. 1992;70(3):633–8.

    Article  CAS  Google Scholar 

  15. Zhang H, et al. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998;58(13):2844–9.

    CAS  PubMed  Google Scholar 

  16. Carvajal RD, et al. Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: a randomized phase 2 trial. J Clin Oncol. 2014;32(suppl 15):10520.

    Google Scholar 

  17. Lesterhuis WJ, et al. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol. 2004;15(supplement 4):iv145–51.

    PubMed  Google Scholar 

  18. Geiger JD, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61:8513–9.

    CAS  PubMed  Google Scholar 

  19. Mackall CL, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14(15):4850–8.

    Article  CAS  Google Scholar 

  20. Krishnadas DK, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3, and NY-ESO-1 for children with relapsed or therapy-refractor neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015;64:1251–60.

    Article  CAS  Google Scholar 

  21. Adair SJ, et al. Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. 2009;58(4):589–601.

    Article  CAS  Google Scholar 

  22. Ma F, et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010;7:381–8.

    Article  CAS  Google Scholar 

  23. Rosenberg S, et al. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Swathi Namburi & Melissa Burgess

Authors
  1. Swathi Namburi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melissa Burgess .

Editor information

Editors and Affiliations

  1. Department of Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA

    Sandra P. D'Angelo

  2. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

    Seth M. Pollack

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Namburi, S., Burgess, M. (2019). Vaccine Therapy in Sarcoma. In: D'Angelo, S., Pollack, S. (eds) Immunotherapy of Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-93530-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93530-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93529-4

  • Online ISBN: 978-3-319-93530-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation